Complement Receptor Type 1 / CD35 (CR1) Antibody (FITC)

Background

CR1 (Complement Receptor 1), also known as CD35, is a membrane-bound glycoprotein that plays a key role in the immune system, primarily in mediating the clearance of immune complexes, apoptotic cells, and pathogens through its interaction with components of the complement system. CR1 acts as a receptor for complement proteins C3b and C4b, which are opsonins involved in the activation of the classical and alternative complement pathways. These pathways are critical for enhancing phagocytosis and immune complex clearance, ultimately contributing to host defense against infections. CR1 is expressed on a variety of immune cells, including erythrocytes (red blood cells), leukocytes, monocytes, macrophages, neutrophils, B cells, follicular dendritic cells, and kidney podocytes. The expression pattern of CR1 allows it to fulfill diverse immunological functions, such as regulating complement activation, promoting phagocytosis, and serving as a cofactor for complement cleavage and degradation.